Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a Neurofibromatosis Clinical Trials Consortium phase II study
Brian Weiss(Cincinnati Children's Hospital Medical Center), Michael J. Fisher(Children's Hospital of Philadelphia), Alan Cantor(Cincinnati Children's Hospital Medical Center), J. Tonsgard(Cincinnati Children's Hospital Medical Center), Roger J. Packer(George Washington University), David Viskochil(University of Utah), Alexander A. Vinks(Cincinnati Children's Hospital Medical Center), Bruce R. Korf(Harvard University), Eva Dombi(Cincinnati Children's Hospital Medical Center), David H. Gutmann(Washington University in St. Louis), Elizabeth K. Schorry(Cincinnati Children's Hospital Medical Center), Pamela L. Wolters(Cincinnati Children's Hospital Medical Center), Brigitte C. Widemann(Cincinnati Children's Hospital Medical Center), John P. Perentesis(Cincinnati Children's Hospital Medical Center), Nicole J. Ullrich(Boston Children's Hospital)
Cited by 147
Related Papers
Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus
|Cell|1990|1.1k
Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation
|Genetics in Medicine|2021|766
Risk stratification of childhood medulloblastoma in the molecular era: the current consensus
|Acta Neuropathologica|2016|650
Proton FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases
|JAMA Oncology|2022|557